Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case
- PMID: 12709675
Persistence of HIV-1 drug resistance mutations and emergence during antiretroviral treatment interruption: considerations from a clinical case
Abstract
Background: HIV drug resistance (HDR) represents a crucial problem in antiretroviral therapy today. HDR mutations can accumulate, persist in the proviral genome and re-emerge, promoting further failure of rescue regimens. Resistance testing on the proviral genome has been suggested in order to detect the presence of archived resistance mutations and to guide drug prescription.
Case report: We report the persistence of HDR mutations to protease inhibitors (PIs) during effective highly active antiretroviral therapy (HAART) not including PIs and their transient re-emergence after treatment interruption. Further follow-up has demonstrated a progressive reversion toward the wild type. At that point in time, proviral DNA analysis was not more sensitive in detecting mutations than tests of the plasma viral load.
Conclusions: This case demonstrates that HDR mutations can persist even though plasma viral load is undetectable, implying the ability of HIV to escape from treatment recycling and the use of drugs to which HIV is cross-resistant. Also, this case suggests that plasmatic and intracellular HIV compartments find a balance under conditions of active viral replication, which could hamper detection of resistance mutations in the proviral DNA. Therefore, in the case of active viral replication, proviral analysis may not actually provide more information than testing the plasma viral load. The clinical utility and specific indications for testing proviral DNA require further investigation.
Similar articles
-
HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time.AIDS. 2006 Jan 9;20(2):159-70. doi: 10.1097/01.aids.0000199820.47703.a0. AIDS. 2006. PMID: 16511408
-
Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.J Clin Virol. 2005 Jul;33(3):206-16. doi: 10.1016/j.jcv.2004.11.006. Epub 2004 Dec 24. J Clin Virol. 2005. PMID: 15911442
-
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.J Med Virol. 2008 Oct;80(10):1695-706. doi: 10.1002/jmv.21261. J Med Virol. 2008. PMID: 18712823
-
Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.Scand J Infect Dis Suppl. 2003;106:79-81. Scand J Infect Dis Suppl. 2003. PMID: 15000591 Review.
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
Cited by
-
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.PLoS Med. 2004 Dec;1(3):e64. doi: 10.1371/journal.pmed.0010064. Epub 2004 Dec 28. PLoS Med. 2004. PMID: 15630469 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical